DE3788902T2 - Hepatitis-Delta-Diagnostika und Impfstoffe, ihre Herstellung und Verwendung. - Google Patents

Hepatitis-Delta-Diagnostika und Impfstoffe, ihre Herstellung und Verwendung.

Info

Publication number
DE3788902T2
DE3788902T2 DE3788902T DE3788902T DE3788902T2 DE 3788902 T2 DE3788902 T2 DE 3788902T2 DE 3788902 T DE3788902 T DE 3788902T DE 3788902 T DE3788902 T DE 3788902T DE 3788902 T2 DE3788902 T2 DE 3788902T2
Authority
DE
Germany
Prior art keywords
vaccines
diagnostics
manufacture
hepatitis delta
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3788902T
Other languages
English (en)
Other versions
DE3788902T3 (de
DE3788902D1 (de
Inventor
Michael Houghton
Kang-Sheng Wang
Qui-Lim Choo
Amy Joan Weiner
Lacy Rasco Overby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26732482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3788902(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of DE3788902D1 publication Critical patent/DE3788902D1/de
Publication of DE3788902T2 publication Critical patent/DE3788902T2/de
Publication of DE3788902T3 publication Critical patent/DE3788902T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5765—Hepatitis delta antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10111—Deltavirus, e.g. hepatitis delta virus
    • C12N2760/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/823—Lower fungi, e.g. mold
    • Y10S530/824—Yeasts
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE3788902T 1986-06-17 1987-06-17 Hepatitis-Delta-Diagnostika und Impfstoffe, ihre Herstellung und Verwendung. Expired - Lifetime DE3788902T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87533786A 1986-06-17 1986-06-17
US875337 1986-06-17
US5399187A 1987-05-22 1987-05-22
US53991 1987-05-22

Publications (3)

Publication Number Publication Date
DE3788902D1 DE3788902D1 (de) 1994-03-10
DE3788902T2 true DE3788902T2 (de) 1994-08-11
DE3788902T3 DE3788902T3 (de) 2004-11-25

Family

ID=26732482

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3788902T Expired - Lifetime DE3788902T3 (de) 1986-06-17 1987-06-17 Hepatitis-Delta-Diagnostika und Impfstoffe, ihre Herstellung und Verwendung.

Country Status (7)

Country Link
US (5) US5378814A (de)
EP (1) EP0251575B2 (de)
JP (4) JP2661044B2 (de)
CA (1) CA1338800C (de)
DE (1) DE3788902T3 (de)
ES (1) ES2061500T5 (de)
HK (1) HK102595A (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3788902T3 (de) * 1986-06-17 2004-11-25 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Hepatitis-Delta-Diagnostika und Impfstoffe, ihre Herstellung und Verwendung.
US4962037A (en) * 1987-10-07 1990-10-09 United States Of America Method for rapid base sequencing in DNA and RNA
IT1241003B (it) * 1990-11-05 1993-12-27 Sorin Biomedica Spa Procedimento per la purificazione di un polipeptide ricombinante hdag equivalente, polipeptide hdag equivalente e saggi immunologici che lo utilizzano
IT1255660B (it) * 1992-06-08 1995-11-09 Sorin Biomedica Spa Composizioni stabilizzate di hdag.
US5445932A (en) * 1992-11-17 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Method for detection of a new marker associated with hepatitis delta virus infection
US5824507A (en) * 1994-05-20 1998-10-20 Genelabs Technologies, Inc. Hepatitis G virus and molecular cloning thereof
US6127116A (en) 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US7235394B1 (en) 1995-08-29 2007-06-26 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
CA2270401A1 (en) 1996-10-31 1998-05-07 Biogen, Inc. Novel hepatitis b virus inhibitors
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
US7049428B1 (en) * 1998-03-04 2006-05-23 Washington University HCV variants
US6844171B1 (en) * 1998-07-02 2005-01-18 President And Fellows Of Harvard College Oligomerization of hepatitis delta antigen
RU2130778C1 (ru) * 1998-07-31 1999-05-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
CA2352738A1 (en) 1998-12-04 2000-06-08 Biogen, Inc. Hbv core antigen particles with multiple immunogenic components attached via peptide ligands
EP1141313A2 (de) 1998-12-31 2001-10-10 Chiron Corporation Verbesserte exprimierung von hiv polypeptiden und herstellung von virusähnliche partikeln
AU2875700A (en) 1999-02-26 2000-09-14 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
EP2275133A1 (de) 1999-02-26 2011-01-19 Novartis Vaccines and Diagnostics, Inc. Verwendung von Bioklebstoffen und Impfstoff-Adjuvantien für mucosale Verabreichung von antigenem Material
WO2000061772A2 (en) 1999-04-14 2000-10-19 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US7196066B1 (en) * 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
CA2405502A1 (en) * 2000-03-29 2001-10-04 Georgetown University Method of treating hepatitis delta viral infection
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
JPWO2002068655A1 (ja) * 2001-02-27 2004-06-24 財団法人理工学振興会 Ｄ型肝炎治療剤の探索方法
FR2830019B1 (fr) * 2001-09-24 2005-01-07 Assist Publ Hopitaux De Paris Molecules d'acides nucleiques d'hdv, leurs fragments et leurs apllications
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
EP2572707A3 (de) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Mikropartikel mit adsorbierten polypeptidhaltigen Molekülen
US7598421B2 (en) * 2002-05-08 2009-10-06 Ucl Biomedica Plc Materials for the delivery of biologically-active material to cells
AU2003269220A1 (en) * 2002-09-27 2004-04-19 Powderject Research Limited Nucleic acid constructs for gene expression
US8034378B2 (en) 2002-12-27 2011-10-11 Novartis Vaccines And Diagnostics, Inc Immunogenic compositions containing phospholipid
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
JP5557415B2 (ja) 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US20060165716A1 (en) 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
EP2357000A1 (de) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Mukosale und systemische Immunisierungen mit Alphavirus-Replikonpartikeln
WO2007052163A2 (en) 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
EP1998800A2 (de) 2006-01-18 2008-12-10 University Of Chicago Zusammensetzungen und verfahren in verbindung mit stayphylokokken-bakterienproteinen
CA2647100A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
ATE539079T1 (de) * 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
EP2007765B1 (de) * 2006-03-23 2012-06-27 Novartis AG Immunstimulierende verbindungen
US20090010948A1 (en) * 2006-12-15 2009-01-08 The University Of Hong Kong Anti-tumor vaccines delivered by dendritic cells devoid of interleukin-10
MX2010002773A (es) 2007-09-12 2010-03-31 Novartis Ag Antigenos mutantes de gas57 y anticuerpos de gas57.
EP3067048B1 (de) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Zusammensetzungen zur induzierung von immunreaktionen
EP2537857B1 (de) 2007-12-21 2017-01-18 GlaxoSmithKline Biologicals SA Mutante Formen von Streptolysin O
CN103897045A (zh) 2009-01-12 2014-07-02 诺华股份有限公司 抗革兰氏阳性细菌疫苗中的Cna_B结构域
WO2010103017A2 (en) 2009-03-09 2010-09-16 William Henry Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
SI2694087T1 (sl) * 2011-04-01 2015-05-29 Novartis Ag Zdravljenje zaradi infekcije z virusom hepatitisa B samim ali v kombinaciji z virusom hepatitisa delta in povezanih jetrnih obolenj
EP3785031A1 (de) 2018-05-17 2021-03-03 Universität Heidelberg Verfahren und mittel zum schnellen nachweis von hdv-infektionen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI86437C (fi) * 1978-12-22 1992-08-25 Biogen Inc Foerfarande foer framstaellning av polypeptider med de antigena egenskaperna hos ett hepatitis b- virusantigen.
EP0182442B2 (de) * 1978-12-22 1996-04-03 Biogen, Inc. Rekombinante DNS-Moleküle und Verfahren zur Herstellung derselben
DE3116882A1 (de) * 1980-06-27 1982-01-21 Univ Georgetown Stabile form des zur hepatitis b gehoerenden delta-antigens und verfahren zu seiner isolierung
DE3479158D1 (en) * 1983-03-04 1989-08-31 Noctech Ltd Diagnostic agent, a process for its preparation and its use in diagnostic methods
US4708871A (en) * 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
EP0131974A1 (de) * 1983-06-08 1985-01-23 Akzo N.V. Bestimmung von delta-Antigenen in Körperflüssigkeiten
ATE73349T1 (de) * 1984-06-18 1992-03-15 Chiron Corp Hepatitisoberflaechenantigenpartikelvakzin.
NL192267C (nl) * 1984-07-31 1997-04-03 Tno Deoxyribonucleïnezuur, micro-organisme, diagnostisch hulpmiddel voor het vaststellen van HDV infectie en gebruik daarvan.
EP0175261B1 (de) * 1984-09-12 1991-12-11 Chiron Corporation Hybridpartikel-Immunogene
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
DE3788902T3 (de) * 1986-06-17 2004-11-25 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Hepatitis-Delta-Diagnostika und Impfstoffe, ihre Herstellung und Verwendung.
US5225347A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors

Also Published As

Publication number Publication date
HK102595A (en) 1995-06-30
EP0251575B1 (de) 1994-01-26
US5932219A (en) 1999-08-03
US5378814A (en) 1995-01-03
JPS63316796A (ja) 1988-12-26
JP2661044B2 (ja) 1997-10-08
ES2061500T3 (es) 1994-12-16
JP2823551B2 (ja) 1998-11-11
JPH09309844A (ja) 1997-12-02
JPH0867693A (ja) 1996-03-12
JP2810004B2 (ja) 1998-10-15
CA1338800C (en) 1996-12-17
EP0251575B2 (de) 2002-11-13
DE3788902T3 (de) 2004-11-25
DE3788902D1 (de) 1994-03-10
JP2635018B2 (ja) 1997-07-30
US5747044A (en) 1998-05-05
ES2061500T5 (es) 2003-05-16
JPH0848694A (ja) 1996-02-20
US5750350A (en) 1998-05-12
EP0251575A1 (de) 1988-01-07
US5389528A (en) 1995-02-14

Similar Documents

Publication Publication Date Title
DE3788902T2 (de) Hepatitis-Delta-Diagnostika und Impfstoffe, ihre Herstellung und Verwendung.
ATE89560T1 (de) Makrolid-derivate, ihre herstellung und ihre verwendung.
DE3885534D1 (de) Arylphosphorderivate, ihre Herstellung und Verwendung.
DE3884140T2 (de) Azazyklische Verbindungen, ihre Herstellung und ihre Verwendung.
ATE123030T1 (de) Piperidin-derivate, ihre herstellung und ihre verwendung.
DE3768922D1 (de) Anthrapyridon-verbindungen, ihre herstellung und ihre verwendung.
DE3777366D1 (de) 2,3-dihydro-cumaron-derivate, ihre herstellung und verwendung.
DE3581578D1 (de) Antikoerper, herstellung und verwendung.
DE69008454T2 (de) Nitrolsothiolderivate, ihre Herstellung und Verwendung.
DE3879024D1 (de) Pyridinium-derivate, ihre herstellung und verwendung.
DE3765682D1 (de) Thiolactam-n-essigsaeure-derivate, ihre herstellung und verwendung.
DE3777604D1 (de) Makrolid-verbindungen, ihre herstellung und ihre verwendung.
DE3784602T2 (de) Inonos-derivate, ihre herstellung und verwendung.
DE3774718D1 (de) Benzothiazolylazolidine und ihre herstellung und verwendung.
DE3883297D1 (de) Phenolderivate, ihre herstellung und verwendung.
DE3784046T2 (de) Pulverfoermige emulgiermittelzubereitung, ihre herstellung und verwendung.
DE68908389T2 (de) Amidofluoroverbindungen, ihre herstellung und ihre verwendung.
DE68919259D1 (de) N-Phenylimide, ihre Herstellung und Verwendung.
DE3879328T2 (de) Stannosilikate, ihre herstellung und verwendung.
DE3770299D1 (de) 1,2,4-triazinonderivate, ihre herstellung und verwendung.
ATE100857T1 (de) Hepatitis-delta-diagnostika und impfstoffe, ihre herstellung und verwendung.
DE3762857D1 (de) 1-aminomethylnaphthalin-6-sulfonsaeure, ihre herstellung und ihre verwendung.
DE59003728D1 (de) 4-Aryl-2-halogenimidazol-5-carbonsäureester, ihre Herstellung und Verwendung.
PT85600A (de) 3-brom-2,6-dimethoxibenzamide ihre herstellung und verwendung
ATE86599T1 (de) Inonos-derivate, ihre herstellung und verwendung.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8332 No legal effect for de
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US